Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska +515 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
NCT05082259
Recruiting
This is a multi-centre Phase I dose finding and proof-of-concept study of the combination of ASTX660 together with Pembrolizumab with expansion cohorts testing preliminary efficacy in immune-refractory cancers, triple negative breast cancer (TNBC), cervical cancer, and glioblastoma. In contrast to the existing studies combining first-generation cIAP1/2 selective Smac mimetics with immune check point inhibitors, the ASTEROID Phase I clinical trial will be the first trial utilising triple cIAP1/2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Cambridge University Hospitals NHS Trust, Cambridge, Not set +2 locations
Conditions: Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer
Register for Updates
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682
Recruiting
The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits... Read More
Gender:
ALL
Ages:
Between 6 months and 11 years
Trial Updated:
05/15/2025
Locations: Leo Pharma Investigational site, Birmingham, Alabama +62 locations
Conditions: Atopic Dermatitis
Register for Updates
3D Animation and Models to Aid Management of Fetal CDH
NCT03750266
Recruiting
We wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH. This will both help the parents see what the problem is and also allow the surgeons, who will operate on the baby once it has been born, to see the size of the hole and what organs are in the wrong place.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Jessop Wing Hospital, Sheffield, South Yorkshire
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
Wearable Devices for Patient Monitoring in Long QT Syndrome
NCT06887387
Recruiting
The main research question of this study is whether wearable devices have utility in monitoring patients with Long QT syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Barts and London Hospital NHS Trust, London, Not set
Conditions: Long QT Syndrome
Register for Updates
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037
Recruiting
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Alectinib works in lung cancer patients with a particular mutation in their cancer known as ALK. Investigators now wish to find out if it will be useful in treating patients with other cancer... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/15/2025
Locations: Belfast City Hospital, Belfast, Not set +26 locations
Conditions: Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma, Solid Tumour
Register for Updates
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
NCT04573023
Recruiting
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Gender:
ALL
Ages:
All
Trial Updated:
05/14/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +28 locations
Conditions: Mucopolysaccharidosis II
Register for Updates
BPH Global Registry
NCT05543200
Recruiting
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographic... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Keck Medicine of USC, Los Angeles, California +22 locations
Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Register for Updates
Intensive Weight Loss Intervention Versus Usual Care for Adults With Severe and Complex Obesity
NCT06321458
Recruiting
In this trial, the aim is to assess the clinical benefits and harms, as well as cost-effectiveness of an intensive weight loss (IWL) intervention that includes total dietary replacements, behavioural support and weight-loss medication compared with existing weight management programmes within primary care for people with severe and complex obesity.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/14/2025
Locations: Frederiksberg kommune: Social-, Sundheds- og Arbejdsmarkedsområdet, Frederiksberg, Not set +9 locations
Conditions: Obesity
Register for Updates
Value of Analysing Under-utilised Leftover Tissue (VauLT)
NCT03832062
Recruiting
Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Royal Marsden Hospital NHS Foundation Trust, London, Not set
Conditions: Oncology
Register for Updates
Intensive Weight Loss Intervention Versus Usual Care for Adults With Obesity
NCT06321432
Recruiting
In this trial, the aim is to assess the clinical benefits and harms, as well as cost-effectiveness of an intensive weight loss (IWL) intervention that includes total dietary replacements, behavioural support and weight-loss medication compared with existing weight management programmes within primary care for people with obesity class I or uncomplicated obesity class II or higher.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/14/2025
Locations: The Department of Medicine and the Gastro Unit, Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Not set +8 locations
Conditions: Obesity
Register for Updates
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973851
Recruiting
Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important areas of functioning. To treat MDD, there are several antidepressants available and prescribing medication is a process of trial-and-error. Guidelines do not explicitly advise on the order in which antidepressant medication... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2025
Locations: Medical University Innsbruck, Innsbruck, Not set +11 locations
Conditions: Major Depressive Disorder, Treatment Resistant Depression
Register for Updates